<DOC>
	<DOC>NCT01825785</DOC>
	<brief_summary>This multicenter, randomized, double-blind, placebo-controlled, ascending multiple dose study assesses the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous administration of 6 doses of 1 mg/kg AMG 785 once every 2 weeks or 3 doses of 3 mg/kg AMG 785 every 4 weeks in healthy men or postmenopausal women with low bone mass and 3 doses of 2 mg/kg AMG 785 every 4 weeks or 6 doses of 2 mg/kg AMG 785 every 2 weeks in healthy postmenopausal women with low bone mass.</brief_summary>
	<brief_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<criteria>Healthy males and females between 45 to 80 years of age Postmenopausal females Low bone mineral density 25hydroxyvitamin D ≥ 20 ng/mL Weight ≤ 98 kg (216 lb) and/or height ≤ 196 cm (77 in) Osteoporosis Subjects with fewer than 2 evaluable (by DXA) vertebrae; metal in hips bilaterally that would not allow for at least one evaluable (by DXA) hip; metal in forearms bilaterally that would not allow for at least one evaluable (by DXA) forearm Previous exposure to AMG 785</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>